Photobiomodulation Brain

• Brain damage,dementia
• Emotional (Anxiety and Depression)
• Energy Imbalances
• Skull fracture, intracranial hemorrhage, elevated intracranial pressure, and/or cerebral contusion

1-Wavelength: 1050nm LED

2-20,000 Hz can be adjusted

3-The default frequency setting is 30Hz--the frequency data can not show on the display, but there are some buttons to adjust it.

4- Duration: 0-30 minutes adjustable -

5-The intensity of the LED: 25, 50, 75 or 100% can be adjusted, that is means 4 level can be adjusted .

6- Remote controller ---wireless remote controller

7-Total Max. output power :16W

8-Single LED max. output power: 50mW

9- Operation: It can be controlled manually or by remote controller.

10-The helmet has 12 regions, each regions we can adjust the power intensity , frequency data and time.

Near-infrared PBM functions by improving mitochondrial energy production by stimulating the enzyme CCO and increasing ATP synthesis. COZING-C320 photobiomodulation dementia therapy can result in neuroprotection and help prevent the spread of brain cell death after injury as shown by the long-term development of smaller lesion areas in mice treated with LLLT, when delivered at 4 h post-TBI. Protection against toxins, increased cellular proliferation, and reduction in apoptosis and anti-inflammatory and antiedema effects may also contribute to the mechanisms that underlie the beneficial effects of PBM. The most exciting prospect is the possibility that tLLLT may stimulate both neurogenesis (the ability of the brain to repair itself) and synaptogenesis (encourage cells to form new synaptic connections). This could lead to the application of tLLLT as a treatment modality for neurodegenerative diseases such as dementia disease.

Abstract

Apart from cancer, Alzheimer's disease (AD) and dementia represent one of the most pressing health challenges facing the Western world today. Numerous clinical trials have not shown any significant benefits from tested drugs in stabilizing or reversing the progressive cognitive decline experienced by dementia patients. Although the pathological hallmarks of AD, such as beta-amyloid plaques and tau tangles, are well known, there is still considerable debate regarding the genetic and lifestyle factors that may predispose individuals to developing dementia. Photobiomodulation (PBM) refers to the therapeutic use of red or near-infrared light to stimulate healing, alleviate pain and inflammation, and prevent tissue damage. In recent years, PBM has been explored for various brain disorders, often applied non-invasively by shining light on the head (transcranial PBM).

This review explores the mechanisms of action of transcranial PBM in the brain and summarizes studies that have used this technique to treat animal models of AD. The outcomes of a limited number of clinical trials using transcranial PBM to treat patients with AD and dementia are also discussed.Proposed chromophores for PBM can absorb different wavelengths of light. It is important to note that there is considerable overlap between the chromophores and that near-infrared light absorbed by structured water is likely to have a longer wavelength (>950 nm).